Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

Group 1 - Beam Therapeutics Inc. (BEAM) has shown strong year-to-date performance, returning 10.5%, outperforming the Medical sector average of 5.6% [4] - The Zacks Consensus Estimate for BEAM's full-year earnings has increased by 7.5% over the past quarter, indicating improved analyst sentiment [4] - Beam Therapeutics is ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [3] Group 2 - Beam Therapeutics is part of the Medical - Biomedical and Genetics industry, which consists of 510 companies and is currently ranked 68 in the Zacks Industry Rank [6] - The average return for the Medical - Biomedical and Genetics industry so far this year is 4.3%, indicating that BEAM is performing better than its industry peers [6] - In contrast, Aurora Cannabis Inc. (ACB), another outperforming Medical stock, has returned 41.9% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5][7]